No Data
No Data
聯康生物科技集團:年報2023
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Liankang Biotechnology Group (00690) announced its 2023 annual results. Revenue reached a record high, with profit reaching HK$70.9 million, a significant increase of 84.04% over the previous year
According to the Zhitong Finance App, Liankang Biotechnology Group (00690) announced its annual results for the year ended December 31, 2023. The Group's revenue reached a record high, reaching approximately HK$484.7 million, an increase of 10.1% year-on-year. The sales performance of Pina Generic Gin Peptides was exceptional, with year-on-year increases of 15.0% and 9.54%, respectively. Profit during the year reached approximately HK$70.9 million, a significant year-on-year increase of 84.04%, making it an important milestone for a research biopharmaceutical company. General and administrative expenses as a percentage of revenue decreased from 10.7% to 9.8% during the year due to the Group's continued internal growth
No Data